Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : House Dust Mite Allergen Extract
Therapeutic Area : Immunology
Study Phase : Approved FDF
Recipient : Stallergenes Greer
Deal Size : Undisclosed
Deal Type : Partnership
Stallergenes and Nuance Enter Exclusive Partnership for Actair Sublingual Immunotherapy
Details : The partnership aims for the development and commercialisation of Actair, Stallergenes Greer’s SLIT tablet for the treatment of house dust mite (HDM) induced allergic rhinitis.
Product Name : Actair
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 03, 2025
Lead Product(s) : House Dust Mite Allergen Extract
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Recipient : Stallergenes Greer
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Bentonite
Therapeutic Area : Immunology
Study Phase : Approved FDF
Recipient : Altamira Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Altamira Expands Bentrio Deal with Nuance Pharma For Asia Distribution
Details : Altamira will extend the territory covered by their exclusive license and distribution agreement by Nuance for Bentrio (bentonite) nasal spray by several countries across South East and East Asia.
Product Name : Bentrio
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 16, 2024
Lead Product(s) : Bentonite
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Recipient : Altamira Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Nuance Pharma Announces Dosing of First Patient in ENHANCE China Phase 3 Trial for COPD
Details : RPL554 (ensifentrine) is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-inflammatory benefits for those with COPD.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 10, 2023
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ensifentrine is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-inflammatory benefits for those with COPD.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 06, 2023
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ensifentrine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 07, 2023
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Labcorp
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ensifentrine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 24, 2023
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Labcorp
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bentonite
Therapeutic Area : Immunology
Study Phase : Approved FDF
Recipient : Altamira Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Altamira Therapeutics Announces Launch of Bentrio in Hong Kong by its Partner Nuance Pharma
Details : AM-301, marketed as Bentrio™, is a drug-free nasal spray for personal protection against airborne viruses and allergens. Upon application into the nose, Bentrio™ forms a protective gel layer on the nasal mucosa.
Product Name : Bentrio
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 30, 2022
Lead Product(s) : Bentonite
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Recipient : Altamira Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bentonite,Citric Acid,Propylene Glycol
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : DKSH
Deal Size : Undisclosed
Deal Type : Partnership
Nuance Pharma Announces Partnership With DKSH To Launch Bentrio™ Nasal Spray In Hong Kong And Macau
Details : Under the cooperation agreement, DKSH HK will provide full-agency services including key account management, marketing promotion, supply chain, and distribution for Bentrio (bentonite) Nasal Spray sales operation in Hong Kong and Macau.
Product Name : Bentrio
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 28, 2022
Lead Product(s) : Bentonite,Citric Acid,Propylene Glycol
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : DKSH
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Recipient : Verona Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RPL554 (ensifentrine) met primary endpoint in ENHANCE-2 demonstrating a statistically significant and clinically meaningful improvement in lung function,significantly reduced the rate of COPD exacerbations in the ENHANCE-2 trial.
Product Name : Ohtuvayre
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 19, 2022
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Recipient : Verona Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Verona Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ensifentrine (RPL554) is an investigational, first-in-class, dual inhibitor of the enzymes phosphodiesterase 3 and 4 ("PDE3" and "PDE4") that combines bronchodilator and anti-inflammatory activities in one compound.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 18, 2022
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Verona Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable